What are Corcept Therapeutics's total assets?

Corcept Therapeutics (CORT) holds $814.9M in total assets, down 3.7% year over year.

How much debt does Corcept Therapeutics have?

Corcept Therapeutics carries $9.6M in total debt against $638.0M of shareholders' equity, a debt-to-equity ratio of 0.02.

How much cash does Corcept Therapeutics have?

Corcept Therapeutics holds $110.0M in cash and equivalents.

Can Corcept Therapeutics cover its short-term obligations?

Its current ratio is 2.86 — current assets exceed current liabilities.

Where does Corcept Therapeutics's balance sheet data come from?

Every line is extracted from Corcept Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Corcept Therapeutics CORT Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$121.75M-5.4%	$128.67M-5.1%	$135.55M+104%	$66.33M-14.5%
Short-term investments	$251.66M-1.6%	$255.67M+9.9%	$232.67M-36.3%	$365.34M+150%
Restricted cash	——	——	——	——
Accounts receivable, net	$59.79M+10.8%	$53.98M+31.3%	$41.12M+32.4%	$31.06M+12.4%
Inventories	$11.09M+210%	$3.58M-56.5%	$8.24M-24.6%	$10.93M-15.7%
Prepaid expenses and other current assets	$40.66M+85.8%	$21.88M-20.6%	$27.56M+67.8%	$16.42M+59.2%
Income taxes receivable	$14.6M+284%	$3.8M—	——	——
Total current assets	$485.46M+2.9%	$471.6M+2.8%	$458.64M-8.1%	$499.25M+87.4%
Property and equipment, net	$1.89M-29.7%	$2.69M+1,279%	$195K-69.2%	$633K-36.8%
Operating lease right-of-use assets	458,300,000%-74,100,000%	532,400,000%+520,400,000%	12,000,000%-102,300,000%	114,300,000%+62,900,000%
Other non-current assets	$5.15M-22.0%	$6.61M+1.1%	$6.54M+29.3%	$5.06M+64.1%
Available-for-sale securities	$511.7M-10.8%	$573.94M+48.3%	$387.02M-4.8%	$406.67M+262%
Total assets	$836.65M-0.5%	$840.55M+35.2%	$621.52M+6.5%	$583.43M+37.7%
Accounts payable	$40.44M+163%	$15.38M-11.6%	$17.4M+45.3%	$11.98M+73.4%
Accrued expenses	$90.6M-0.1%	$90.7M+548%	$14M0.0%	$14M—
Operating lease liabilities, current	$1.08M+30.8%	$829K+449%	$151K-86.8%	$1.14M+117%
Accrued interest	$4.1M0.0%	$4.1M—	——	——
Total current liabilities	$166.09M+18.0%	$140.77M+34.7%	$104.51M+44.2%	$72.49M+52.5%
Operating lease liabilities, non-current	$5.02M-17.8%	$6.11M—	$0—	——
Operating Lease Liabilities (Total)	$6.11M-12.0%	$6.94M+4,493%	$151K-86.8%	$1.14M+117%
Total liabilities	$188.85M+17.3%	$160.96M+40.2%	$114.81M+40.7%	$81.59M+70.2%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	$140K+2.9%	$136K+2.3%	$133K+1.5%	$131K+3.1%
Additional paid-in capital	$968.6M+16.4%	$832.11M+12.7%	$738.52M+11.5%	$662.34M+12.0%
Retained earnings	$643.39M+18.3%	$543.74M+35.1%	$402.53M+35.8%	$296.39M+52.0%
Accumulated other comprehensive income (loss)	$2.26M+1,143%	-$217K-136%	$609K+170%	-$869K-283%
Treasury stock	$966.59M+38.8%	$696.17M+9.6%	$635.08M+39.2%	$456.15M+11.1%
Total stockholders' equity	$647.81M-4.7%	$679.59M+34.1%	$506.71M+1.0%	$501.84M+33.5%
Total liabilities and stockholders' equity	$836.65M-0.5%	$840.55M+35.2%	$621.52M+6.5%	$583.43M+37.7%
Short- term Investments	$251.66M-1.6%	$255.67M+9.9%	$232.67M-36.3%	$365.34M+150%
Other current assets	$7.1M+16.8%	$6.08M+3.3%	$5.88M—	——
Available-for-Sale Securities (Non-Current)	$160.27M-27.1%	$219.83M+284%	$57.18M+1,056%	$4.95M-95.6%
Deferred Tax Assets and Other Non-Current Assets	$5.15M-22.0%	$6.61M+1.1%	$6.54M+29.3%	$5.06M+64.1%
Net Investment in Lease	$4.58M-13.9%	$5.32M+4,337%	$120K-89.5%	$1.14M+122%
Deferred tax assets	$168.2M+28.5%	$130.91M+44.5%	$90.61M+47.4%	$61.47M+124%
Long- term Investments	$160.27M-27.1%	$219.83M+284%	$57.18M+1,056%	$4.95M-95.6%
Operating lease right-of-use assets	$4.58M-13.9%	$5.32M+4,337%	$120K-89.5%	$1.14M+122%
Other non-current assets	$5.15M-22.0%	$6.61M+1.1%	$6.54M+29.3%	$5.06M+64.1%
Operating Lease Right-of-Use Assets in Other Assets	$4.58M-13.9%	$5.32M+4,337%	$120K-89.5%	$1.14M+122%
Software and Technology Licenses, Net	$5.15M-22.0%	$6.61M+1.1%	$6.54M+29.3%	$5.06M+64.1%
Accrued Contingent Liabilities	——	——	——	——
Accrued Marketing and Advertising Expenses	$10.61M+217%	$3.35M+88.9%	$1.77M+308%	$434K-48.5%
Other Commercial Liabilities	$90.6M-0.1%	$90.7M+75.7%	$51.63M+67.6%	$30.8M+11.3%
Accrued research and development expenses	$33.95M+0.3%	$33.87M+58.8%	$21.33M+46.4%	$14.57M+17.1%
Accrued Liabilities, Current	$90.6M-0.1%	$90.7M+75.7%	$51.63M+67.6%	$30.8M+11.3%
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——
Marketing and selling	$10.61M+217%	$3.35M+88.9%	$1.77M+308%	$434K-48.5%
Total debt	$6.11M-12.0%	$6.94M+4,493%	$151K-86.8%	$1.14M+117%
Additional paid-in capital	$968.6M+16.4%	$832.11M+12.7%	$738.52M+11.5%	$662.34M+12.0%
Accrued compensation	$37.4M-10.4%	$41.73M+63.9%	$25.46M+64.1%	$15.51M—
Short-term accrued government rebates	$35.68M-14.2%	$41.58M+125%	$18.47M+66.4%	$11.1M-0.7%
Income taxes payable – long-term	$15.18M+7.8%	$14.08M+36.6%	$10.31M+13.3%	$9.1M+2,124%
Clinical deposits	$5.24M+188%	$1.82M-53.0%	$3.87M—	——
Estimated Fair Value	$511.7M-10.8%	$573.94M—	——	——
Deferred clinical materials	$5.06M+12.6%	$4.49M-66.7%	$13.5M—	——
Inventory Current Noncurrent	$23.96M+49.8%	$16M+0.1%	$15.97M-6.2%	$17.03M-5.1%
Finished goods	$9.41M+14.7%	$8.21M+6.0%	$7.74M-15.9%	$9.2M+41.6%
Raw materials	$847K—	$0—	——	——
Work in progress	$13.7M+75.9%	$7.79M-5.4%	$8.23M+5.2%	$7.83M-31.6%
Lessee Operating Lease Liability Payments Due	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
Rentable area	40.9K—	——	——	——
Long-term accrued government rebates	$2.56M—	$0—	——	——
Loss Contingency Accrual	——	——	——	——
Obligated base rent	$1M—	——	——	——
Operating Lease Weighted Average Discount Rate Percent	——	——	——	——
Other accrued liabilities	$6.91M+71.0%	$4.04M-25.0%	$5.39M+588%	$783K-3.2%
Prepaid expenses	$23.26M+145%	$9.49M+120%	$4.32M—	——
Purchase Obligation	——	——	——	——
Commitment to purchase API	——	——	——	——
Purchase Obligation	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Corcept Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Corcept Therapeutics's total assets?: Corcept Therapeutics (CORT) holds $814.9M in total assets, down 3.7% year over year.
How much debt does Corcept Therapeutics have?: Corcept Therapeutics carries $9.6M in total debt against $638.0M of shareholders' equity, a debt-to-equity ratio of 0.02.
How much cash does Corcept Therapeutics have?: Corcept Therapeutics holds $110.0M in cash and equivalents.
Can Corcept Therapeutics cover its short-term obligations?: Its current ratio is 2.86 — current assets exceed current liabilities.
Where does Corcept Therapeutics's balance sheet data come from?: Every line is extracted from Corcept Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.